Delafloxacin is a fluoroquinolone antibiotic used to treat bacterial infections, including acute bacterial skin and skin structure infections (ABSSSI) and complicated urinary tract infections (cUTIs). It is effective against a broad range of bacteria, including both Gram-positive and Gram-negative organisms. Notably, it shows strong activity against methicillin-resistant Staphylococcus aureus (MRSA), making it valuable in treating infections where other antibiotics may fail.

Delafloxacin can be administered intravenously or orally, allowing for flexible treatment options from hospital to outpatient settings. Its unique chemical structure enhances its potency in acidic environments, improving effectiveness in infected tissues with low pH, such as abscesses.

It is particularly useful for patients at risk of recurrent infections or with compromised immune systems, due to its broad spectrum and good tissue penetration.